Cliniques universitaires Saint-Luc- Université Catholique de Louvain

saintluc.be

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

343

Active

53

Phase 3

6

Total enrollment

54,282

Pipeline matrix

Showing 6 of 6 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Sirolimus2
Genetic dissection of Fibromuscular Dysplasia1
Immunotherapeutic Agent1
Molecular Target1
GLP-1 Receptor Agonists1
biomarker1

Next readouts

  • 2022-12-31
  • 2025-04-01
  • 2028-05
  • 2028-12
  • 2056-12-31

Top conditions

  • Healthy19
  • Cystic Fibrosis14
  • Stroke11
  • Surgery6
  • Head and Neck Cancer5
  • Parkinson Disease5
  • Squamous Cell Carcinoma of the Head and Neck4
  • Covid194

Frequently asked questions about Cliniques universitaires Saint-Luc- Université Catholique de Louvain

How many clinical trials does Cliniques universitaires Saint-Luc- Université Catholique de Louvain have on ClinicalTrials.gov?
Cliniques universitaires Saint-Luc- Université Catholique de Louvain is listed as the lead sponsor on 343 clinical trials in ClinicalTrials.gov, 53 of which are currently active (recruiting, enrolling, or ongoing).
How many of Cliniques universitaires Saint-Luc- Université Catholique de Louvain's trials are in Phase 3?
6 of Cliniques universitaires Saint-Luc- Université Catholique de Louvain's trials are in Phase 3, spread across 6 active drug programs.
What therapeutic areas does Cliniques universitaires Saint-Luc- Université Catholique de Louvain focus on?
Cliniques universitaires Saint-Luc- Université Catholique de Louvain's most-studied conditions on ClinicalTrials.gov are Healthy, Cystic Fibrosis, Stroke, Surgery, Head and Neck Cancer.
When are Cliniques universitaires Saint-Luc- Université Catholique de Louvain's next clinical trial readouts?
Cliniques universitaires Saint-Luc- Université Catholique de Louvain has 5 upcoming primary-completion readouts tracked here; the soonest is “European/International FMD Registry and Initiative”, expected around 2022-12-31.